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Abstract 
Cryoglobulinemia induces an immune complex-mediated glomerulonephritis that is 
characterized by the presence of large immune deposits, including complement C3 and C5b-
9, marked macrophage influx and mesangial cell proliferation. The precise role of 
complement in cryoglobulin-induced glomerulonephritis in humans remains unclear, 
whereas in mice there has been evidence that complement activation might be a central 
factor favoring glomerular inflammation, particularly by the recruitment of neutrophils. We 
report on an exceptional case of cryoglobulin-induced glomerulonephritis in a patient with 
mixed essential cryoglobulinemia type II. The clinical features included relapsing proteinuria 
and renal function impairment that were controlled by plasmapheresis. Complement was 
low in plasma and two renal biopsies at 1-year interval showed prominent immunoglobulin 
and complement deposits, with unusual high numbers of neutrophils. In a 1-patient clinical 
trial, we tested whether the monoclonal anti-C5 antibody eculizumab would be sufficient to 
control renal function at the time of a relapse. Although during the initial weeks renal 
function was stabilized, slow increase in creatinine could not be controlled by this treatment, 
so that plasmapheresis was reinstituted. This result suggests that despite evidence for a role 
of complement in enhancing renal damage in this patient, other inflammatory processes 
dominated. 
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Introduction 
In humans, cryoglobulinemia can be responsible for a membranoproliferative 
glomerulonephritis (MPGN), which is characterized by the formation and/or deposition 
of immunoglobulins (Igs) and complement in the glomeruli, followed by an influx of 
inflammatory cells [1–3]. However, the mechanisms inducing the glomerular 
inflammation are not fully understood. Complement is well known to mediate the 
processing of immune complexes [4]. Since the early studies to investigate complement 
activation by immune complexes in experimental nephrotoxic nephritis, the 
complement system has been considered to play an important proinflammatory role in 
the glomerulus [5, 6]. In cryoglobulinemia, however, there is no clear evidence that 
complement activation is central in mediating tissue damage by immune deposits. 
Results have been obtained in mice by Trendelenburg et al. [7], who analyzed the role 
of complement in the pathogenesis of initial glomerular inflammation induced by 
murine 6–19 IgG3 monoclonal cryoglobulins. They used two different strains of mice 
developing either type I or II cryoglobulinemia. Their results indicated that 
complement C5 has a predominant role in neutrophil recruitment as C5-deficient mice 
had significantly reduced glomerular infiltration by polymorphonuclear neutrophils 
[7]. This is of particular interest, as the monoclonal complement C5-blocking antibody 
eculizumab could offer a promising therapeutic option for patients with cryoglobulin-
induced glomerulonephritis. 
Cryoglobulinemia is a rare disease and is characterized by Igs that precipitate in the 
cold. Depending on the clonality of the precipitating Igs, three types of 
cryoglobulinemia can be distinguished [8]. Type I cryoglobulinemia consists of a single 
monoclonal cryoprecipitable Ig, whereas type II and III cryoglobulins are mixed, i.e. 
composed of monoclonal (type II) and polyclonal (type III) antibodies with rheumatoid 
factor activity against other Igs. Mixed cryoglobulinemia may be associated with 
numerous infectious and immunological diseases as well as lymphatic malignancies. In 
particular, mixed cryoglobulinemia type II is strongly associated with chronic hepatitis 
C, and nowadays rarely appears as an isolated disease, i.e. the so-called essential 
cryoglobulinemia [9]. Clinically, cryoglobulinemia manifests itself with symptoms like 
weakness and arthralgias and variable cutaneous and visceral organ involvement [9, 
10]. Overall, the prognosis is dependent on the underlying disease and affected organs. 
It is poorer in patients with renal involvement, liver failure, lymphoproliferative 
disease and malignancies [9]. The treatment of cryoglobulinemia is challenging. 
Steroids suppress inflammation with success in some patients, but additional 
plasmapheresis to remove circulating cryoglobulins and immunosuppressive treatment 
to inhibit the formation of new cryoglobulins are often necessary [11–13]. All of these 
therapies are characterized by serious side effects. 
Eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, Conn., USA) is a monoclonal 
antibody that targets complement C5 and prevents the cytolytic and proinflammatory 
effects of complement activation [14]. Eculizumab is approved for the treatment of 
patients with paroxysmal nocturnal hemoglobinuria. It effectively reduces 
intravascular hemolysis, thereby improving anemia and quality of life and decreases 
transfusion requirements [15, 16]. Since the initial validation of inhibition of a 
complement component as a therapeutic target, the field for the use of eculizumab has 
been expanded [17]. Recently, eculizumab has been approved from the FDA for the 
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treatment of patients with atypical hemolytic uremic syndrome, in whom the control of 
complement activation is insufficient. Furthermore, eculizumab has been successfully 
used preemptive prior to kidney transplantation [18, 19] or postoperatively to prevent 
disease recurrence in the allograft [20–22] in several cases with complement disorder-
associated atypical hemolytic uremic syndrome. 
Here, we report on an exceptional case of mixed essential cryoglobulinemia with 
severe glomerulonephritis characterized by a prominent infiltration of the glomeruli by 
neutrophils. A 1-patient clinical trial of eculizumab was attempted to investigate 
whether complement inhibition would be sufficient to inhibit this relapsing 
glomerulonephritis. The initial partial response was, however, not sustained, and the 
patient returned to intermittent plasmapheresis.  
Case Report and Therapeutical Trial 
A 55-year-old woman was diagnosed with a mixed type II cryoglobulinemia (monoclonal IgM-
kappa and polyclonal IgG) and immune complex-mediated glomerulonephritis in May 2006. She 
developed an acute nephritic syndrome with pathological urinary sediment (i.e. dysmorphic 
erythrocytes, cellular casts and leucocytes), high proteinuria (7 g/day), arterial hypertension, volume 
overload and moderate renal function impairment, which got worse over time. Further, she suffered 
from weakness and arthralgias, but other organ manifestations besides the kidney were not present. 
The first renal biopsy showed endocapillary hypercellularity with infiltration of mononuclear cells, an 
unusual high number of neutrophils, and subendothelial immune deposits, which were positive for 
IgM as well as complement C3 and C5b-9, resembling acute poststreptococcal glomerulonephritis; 
however, classical humps were missing (fig. 1). Comprehensive blood examinations revealed 
cryoglobulins (0.6 g/l), a monoclonal IgM (2 g/l), hypogammaglobulinemia (<5 g/l), and low 
complement C3 and C4 levels. Extensive screening for an infectious disease (i.e. serological testing 
and PCR for HIV, HCV, HBV, CMV and EBV) and malignancy (bone marrow biopsy, computed 
tomography of the chest and abdominal organs) was negative. Further, autoantibodies were negative 
(ANA, ANCA, anti-DNA, antiphospholipid antibodies) except for rheumatoid factor, with a titer 
>1/10,000. A second renal biopsy 1 year later showed early stage MPGN with a still high number of 
neutrophils, which was interpreted as a progression of disease. 
The patient was unresponsive to high-dose steroids and subsequently received cyclophosphamide 
pulse therapy, mycophenolat mofetil and two courses of the monoclonal anti-CD20 antibody 
rituximab. These immunosuppressive therapies all failed to get the cryoglobulin-induced 
glomerulonephritis under control. On October 2006, once to twice weekly plasmapheresis was started 
with success. However, plasmapheresis was complicated by two catheter-related blood stream 
infections. In addition, she suffered from headache and complained about unpleasant diaphoresis 
during the procedures. At the request of the patient, plasmapheresis was interrupted several times 
with prompt disease relapses manifested by an increase in serum creatinine and proteinuria, and 
reinstitution of intensive plasmapheresis. Thus, we designed a protocol to test whether eculizumab 
could replace plasmapheresis at the time of a relapse. The protocol was approved by the local ethical 
committee, and informed consent was provided in accordance with the Declaration of Helsinki. 
Criteria for treatment success were: (i) prevention of progression as determined by maintenance or 
improvement in renal function, (ii) reduction of proteinuria, and (iii) no appearance of new extrarenal 
disease manifestations.  
In June 2011, the study was started after the last series of plasma exchange, with a continuous 
surveillance of renal function and clinical signs of relapse. As expected from previous intervals 
between plasmapheresis series, it took 3 weeks until relapse. Eculizumab was dosed at 900 mg 
intravenously every 7 days for 4 weeks, at 1,200 mg 7 days later, and another dose of 1,200 mg 14 
days later. At that time of initiating eculizumab therapy, serum creatinine level was 340 µmol/l (eGFR 
13 ml/min), proteinuria was 8 g/day and the patient still had nephritic urinary sediment. The patient 
had been vaccinated against Neisseria meningitis 14 days prior to receive the first dose of eculizumab. 
Fig. 2 shows the clinical course and renal function (i.e. serum creatinine and proteinuria), before and 
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after initiating eculizumab. Blood samples were drawn to control blood concentrations of eculizumab 
and blockage of the complement system during the treatment. Complement activity was shown to be 
blocked using a hemolytic assay (CH50) and by the drop to background of the high levels of soluble 
C5b-9 (MicroVue® Complement SC5b-9 Plus; Quidel Corporation, San Diego, Calif., USA) (data not 
shown). As expected, complement C3 and C4 levels remained low during eculizumab therapy. The 
eculizumab infusions were well tolerated and the patient reported an improvement in her well-being. 
Nevertheless, without plasmapheresis the blockage of the terminal complement was not sufficient to 
control the disease. Proteinuria remained at high levels of 6–8 g/day, hematuria persisted and renal 
function remained stable for some weeks before deteriorating. After 7 weeks of therapy, the patient 
was urgently admitted to hospital because of fluid overload. Plasmapheresis was restarted and renal 
function returned almost to baseline level (fig. 2). 
Discussion 
To our knowledge, this is the first report of a clinical trial to investigate the 
monoclonal complement inhibitor eculizumab in a patient with mixed 
cryoglobulinemia and severe glomerulonephritis. The unique features of the 
cryoglobulinemic MPGN in this patient were the resistance to treatments such as 
steroids, cyclophosphamide and rituximab, the presence of high numbers of 
neutrophils in two renal biopsies taken at 1-year interval (on both occasions at the time 
of a severe relapse), and the prompt response to plasmapheresis. All these features 
suggested that complement was a major player in the disease process: indeed 
complement was activated and deposited in the glomeruli, and complement factor C5a 
is known to be a highly active chemotactic agent for neutrophils. In addition, recently 
macrophages have been shown to be central to the nephritis in a model of murine 
cryoglobulinemic MPGN [3]. 
The improvement felt by the patient and the stabilization of the creatinine level after 
initiation of eculizumab suggested that complement might be involved in the 
inflammation and tissue damage induced by cryoglobulins. However, it became evident 
after 7 weeks that there was no improvement, rather a slow deterioration of renal 
function with ongoing signs of active nephritis in the urinary sediment. Thus, 
eculizumab therapy was stopped. Evidently complement blockade at the C5 level alone 
was insufficient. This observation does, however, not exclude a role for complement in 
cryoglobulin-induced glomerulonephritis. For instance, we do not know whether 
complement blockade would prevent a relapse, i.e. whether complement might induce 
a cascade of inflammatory events, which then become independent of continuous 
complement activation. Further, one can argue that the blockage of C5 by eculizumab 
plays a central role to prevent the chemotactic function of C5a for the recruitment of 
neutrophils. Once they have invaded the glomerulus where the inflammatory processes 
take place, they act independently of complement C5a, which has no proinflammatory 
effects. This would be an argument for a prophylactic and sustained use of eculizumab 
in patients with cryoglobulinemia when the disease is in remission and against its use 
as a salvage therapy in disease relapse, to induce a more prolonged remission or reduce 
the frequency of relapses. This argumentation is supported by the mouse model 
reported by Trendelenburg et al. [7], where the C5-deficient mice had impressively less 
influx of neutrophils, as their experimental model of cryoglobulin-induced 
glomerulonephritis rather resembles a model of preemptive blockage of C5a to prevent 
glomerular inflammation just at the beginning and not when the inflammatory process 
is fully developed as it is in case of a relapse. In addition, eculizumab will not prevent 
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the deposition of C3 fragments and release of C3a, which by themselves might interact 
with complement receptors on mesangial cells, macrophages/monocytes and 
neutrophils and activate these cells. 
Usually, the development of clinical therapy protocols relies on evidence-based 
guidelines that mainly focus on randomized, controlled trials; however, for rare 
diseases, such as in the present case of essential cyoglobulinemia, treatment options 
rely on similarities to other diseases and the understanding of the pathological process 
on experimental data obtained in animal models. Since human data of cryoglobulinemia 
are scarce, the present 1-patient trial report demonstrating the response to eculizumab 
– whether considered partially positive or negative – might be of use for the medical 
community. 
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Fig. 1. Renal biopsy findings in a patient with a cryoglobulin-induced immune complex 
glomerulonephritis. A Overview showing endocapillary glomerulonephritis with impressive 
hypercellularity. B Section of a glomerulus with mononuclear cells and polymorphonuclear 
neutrophils (indicated by arrows) in the glomerular convolutes. Immune complex-mediated 
glomerulonephritis positive for IgM (C) and complement C3 (D) by immunofluorescence staining. 
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Fig. 2. Clinical course before (A) and after initiation (B) of eculizumab in a patient with a cryoglobulin-
induced glomerulonephritis. Serum creatinine levels and proteinuria in the years before and after 
initiation of eculizumab treatment are shown. Plasmapheresis is also indicated. Prot/Crea = Urine 
protein/creatinine ratio. 
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